AtriCure, Inc. (NASDAQ:ATRC – Get Free Report) has earned an average rating of “Buy” from the seven analysts that are covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have issued a report on the stock in the last year is $49.78.
A number of equities research analysts have recently weighed in on ATRC shares. JPMorgan Chase & Co. lowered their price target on AtriCure from $42.00 to $34.00 and set an “overweight” rating for the company in a report on Thursday. Needham & Company LLC reduced their price target on shares of AtriCure from $46.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday. UBS Group upped their target price on AtriCure from $57.00 to $58.00 and gave the company a “buy” rating in a report on Friday, February 16th. StockNews.com cut AtriCure from a “hold” rating to a “sell” rating in a research report on Wednesday, March 27th. Finally, Oppenheimer upgraded AtriCure from a “market perform” rating to an “outperform” rating and set a $32.00 price objective for the company in a research report on Tuesday, April 23rd.
Check Out Our Latest Research Report on ATRC
Insider Buying and Selling
Hedge Funds Weigh In On AtriCure
Hedge funds have recently modified their holdings of the stock. RiverPark Advisors LLC acquired a new position in shares of AtriCure in the 3rd quarter valued at $27,000. Allspring Global Investments Holdings LLC increased its position in shares of AtriCure by 31.5% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,074 shares of the medical device company’s stock worth $91,000 after acquiring an additional 497 shares in the last quarter. Quest Partners LLC acquired a new stake in shares of AtriCure during the fourth quarter valued at approximately $103,000. Virtu Financial LLC purchased a new stake in shares of AtriCure in the 4th quarter valued at approximately $213,000. Finally, Victory Capital Management Inc. boosted its stake in AtriCure by 22.9% in the 4th quarter. Victory Capital Management Inc. now owns 6,202 shares of the medical device company’s stock worth $221,000 after purchasing an additional 1,155 shares during the period. 99.11% of the stock is currently owned by institutional investors and hedge funds.
AtriCure Trading Down 6.0 %
NASDAQ ATRC opened at $20.89 on Friday. The company’s fifty day moving average price is $28.81 and its two-hundred day moving average price is $33.13. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of -26.11 and a beta of 1.41. AtriCure has a 12 month low of $20.19 and a 12 month high of $59.61. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.57 and a quick ratio of 2.66.
AtriCure (NASDAQ:ATRC – Get Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The medical device company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The company had revenue of $108.90 million for the quarter, compared to the consensus estimate of $106.86 million. AtriCure had a negative return on equity of 7.82% and a negative net margin of 8.98%. The business’s revenue for the quarter was up 16.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.23) EPS. As a group, research analysts predict that AtriCure will post -0.71 earnings per share for the current fiscal year.
About AtriCure
AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.
Further Reading
- Five stocks we like better than AtriCure
- 3 Best Fintech Stocks for a Portfolio Boost
- Appleās Earnings Show Investors Its Strength and Its Weakness
- What is the Dow Jones Industrial Average (DJIA)?
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- How to Find Undervalued Stocks
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.